Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Key PointsNovo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.